Latest Strategic Investment News

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.

Comms Group Limited reported a steady 2% revenue increase to $56.6 million in FY25, hitting the top end of guidance despite margin pressures from global expansion investments. The recent TasmaNet acquisition is on track to drive future growth.

Comms Group delivered FY25 results at the upper end of guidance, boosted by record new sales and the acquisition of TasmaNet. The company sets sights on accelerated growth and integration benefits in FY26.

Austral Gold Limited reported a net loss of US$1.3 million for the first half of 2025, while completing refurbishment of its Casposo plant to diversify production. Despite operational challenges and increased costs, the company leans on shareholder support and strategic investments to manage liquidity pressures.

Dicker Data has reported a robust first half of FY25, with revenue climbing 15.7% driven by AI-related deals and an accelerated PC refresh cycle. The company raised its full-year guidance, signaling confidence despite ongoing market challenges.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Comms Group Limited reported a 2.1% revenue increase to $56.6 million for FY25, driven by organic growth and the strategic acquisition of TasmaNet. Despite this, underlying EBITDA declined 13.6%, reflecting investments and one-off revenue adjustments.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

Knosys Limited reported steady FY25 revenue growth and secured major contract renewals, while investing heavily in AI-driven library technology that positions it for global expansion.